<?xml version="1.0" encoding="UTF-8"?>
<p id="p0170">A comprehensive evaluation of infection risk with dupilumab was conducted by Eichenfield et al.
 <xref rid="bib70" ref-type="bibr">
  <sup>70</sup>
 </xref> Their analysis pooled data from 7 randomized controlled trials in atopic dermatitis, which showed similar infection rates per 100 patient-years in the treatment and placebo groups. Specifically, the rates of viral URIs and influenza infections were lower in the dupilumab groups compared with placebo. Similarly, an observational study by Schneeweiss et al
 <xref rid="bib32" ref-type="bibr">
  <sup>32</sup>
 </xref> found no increase in the rates of serious bacterial or opportunistic infections with dupilumab compared with methotrexate.
</p>
